Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, today announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB. Enable Injections currently has partnerships with five companies to deliver products that shift treatment to the home with easy, convenient self-administration of new large-volume drugs.Read more: https://prn.to/2B3gYr6